Anlon Healthcare IPO Sees 50% Subscription on Day 1: Should You Invest?

The initial public offering (IPO) of Anlon Healthcare has received a lukewarm response on the first day, with a 50% subscription. The retail portion of the IPO has been booked 5 times, indicating a strong interest from individual investors. The company aims to raise Rs 115 crore through the IPO, which will be used to fund its expansion plans and repay debts. Anlon Healthcare is a leading manufacturer of pharmaceutical products, with a strong presence in the domestic market. The company has a diverse product portfolio, with a focus on niche therapeutic segments. The IPO consists of a fresh issue of 63.75 lakh shares and an offer for sale of 21.25 lakh shares by existing shareholders. The price band for the IPO has been fixed at Rs 185-200 per share. The issue will close on September 22, and the shares are expected to be listed on the BSE and NSE on September 30. The company has reported a strong financial performance in the past few years, with a revenue growth of 20% in FY22. The net profit has also increased by 25% during the same period. The company’s debt-to-equity ratio is 0.5, which is relatively low compared to its peers. The IPO has been rated as ‘subscribe’ by several brokerages, citing the company’s strong financial performance and growth prospects. However, some analysts have raised concerns about the company’s dependence on a few large customers and the intense competition in the pharmaceutical industry. The company has a strong management team, with a proven track record of delivering growth. The promoters of the company have a 60% stake, which is expected to remain stable even after the IPO. The company has a strong research and development (R&D) focus, with a dedicated team working on new product development. The company has also established a strong distribution network, with a presence in over 20 states. The IPO is being managed by ICICI Securities, Axis Capital, and IIFL Securities. The company has reported a strong return on equity (ROE) of 20% in FY22, which is higher than its peers. The company’s valuation is reasonable, with a price-to-earnings (P/E) ratio of 20, which is lower than its peers. Overall, the Anlon Healthcare IPO is a good investment opportunity for those looking to invest in the pharmaceutical sector. However, investors should do their own research and consider their own risk tolerance before investing. The company’s strong financial performance, growth prospects, and reasonable valuation make it an attractive investment opportunity. But, the dependence on a few large customers and intense competition in the industry are concerns that need to be considered.

Source